代偿性晚期慢性肝病肝失代偿预测模型:一项系统综述
本系统综述检索MEDLINE至2023年12月,纳入16项回顾性和前瞻性研究,评估代偿性晚期慢性肝病或代偿期肝硬化患者首次失代偿的多变量预测模型。27个预测因子中最常见为白蛋白、血小板、年龄、肝硬度等。仅10/16评价校准度,9/16进行外部验证,13项研究总体偏倚风险高。
要点
- 代偿性晚期慢性肝病失代偿预测模型常描述不充分,外部验证不足。
- 仅10/16研究评价校准度,9/16进行外部验证,13项研究偏倚风险高。
- 无研究专门预测酒精相关性肝病患者的失代偿结局。
核心结论
- 代偿性晚期慢性肝病失代偿预测模型常描述不充分,较少纳入酒精相关性肝病患者,且缺乏外部验证,这些因素阻碍其临床实用性和推广。
- 用于临床时,预测模型必须准确描述未来风险。
研究设计与样本
- 系统综述,检索MEDLINE从建库至2023年12月,研究注册于PROSPERO(CRD42023488395)。
- 纳入16项回顾性和前瞻性研究,其中7项聚焦单一病因。
- 使用PROBAST评估模型偏倚风险和适用性,采用叙述性综合总结结果。
- 报告遵循PRISMA和CHARMS指南。
主要发现
- 共27个预测因子纳入模型,最常见为白蛋白、血小板、年龄、肝硬度、胆红素、国际标准化比值及上消化道内镜下门静脉高压相关表现。
- 所有研究均报告区分度指标,但仅10/16评价校准度。
- 外部验证在9/16项研究中开展。
- 13项研究被评为总体偏倚风险高。
- 无研究专门预测酒精相关性肝病患者的结局,且结局定义不一,部分模型将肝细胞癌与失代偿合并预测。
局限性
- 模型常描述不充分。
- 较少纳入酒精相关性肝病患者。
- 缺乏外部验证。
- 仅10/16研究评价校准度。
- 13项研究总体偏倚风险高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Identifying individuals with compensated advanced chronic liver disease (cACLD) at risk of decompensation allows for personalized therapy. However, predicting decompensation is challenging, and multiple models have been developed. This study systematically appraises the performance and clinical applications of published multivariable models predicting first decompensation in patients with cACLD or compensated cirrhosis. APPROACH AND RESULTS: We searched MEDLINE for liver decompensation prediction models from inception to December 2023. The research was registered with PROSPERO (CRD42023488395). Model risk of bias and applicability were assessed using the Prediction study Risk of Bias Assessment Tool (PROBAST), with results summarized via narrative synthesis. Reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies guidelines. Sixteen studies (retrospective and prospective) were included. Seven focused on a single etiology. No study specifically predicted outcomes in persons with alcohol-associated liver disease. Outcome definitions varied, with some models predicting HCC together with decompensation. In total, 27 predictors were included in the models. The most frequent predictors were albumin, platelets, age, liver stiffness, bilirubin, international normalized ratio, and the presence of portal hypertension-related findings during upper gastrointestinal endoscopy. All studies reported discrimination measures, but only 10/16 evaluated calibration. External validation was conducted in 9/16 studies. Thirteen studies were rated as having a high overall risk of bias. CONCLUSIONS: For clinical utility, a predictive model must accurately describe future risks. Models for predicting decompensation in cACLD are often poorly described, infrequently include patients with ArLD, and lack external validation. These factors are barriers to the clinical utility and uptake of predictive models for first decompensation in patients with cACLD.
引用
- Haghnejad V, Burke L, El Ouahabi S, et al. Prediction models for liver decompensation in compensated advanced chronic liver disease: A systematic review. Hepatology. 2025. PMID: 40262122. doi:10.1097/HEP.0000000000001359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。